Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. [electronic resource]
Producer: 20100902Description: 717-22 p. digitalISSN:- 1537-6613
- ATP Binding Cassette Transporter, Subfamily B
- ATP Binding Cassette Transporter, Subfamily B, Member 1 -- genetics
- Alkynes
- Anti-HIV Agents -- pharmacokinetics
- Aryl Hydrocarbon Hydroxylases -- genetics
- Benzoxazines -- pharmacokinetics
- Black People
- Cyclopropanes
- Cytochrome P-450 CYP2B6
- Cytochrome P-450 CYP3A -- genetics
- Female
- HIV Infections -- drug therapy
- Hispanic or Latino
- Humans
- Male
- Oxidoreductases, N-Demethylating -- genetics
- Pharmacogenetics
- Polymorphism, Single Nucleotide
- Reverse Transcriptase Inhibitors -- pharmacokinetics
- Treatment Outcome
- White People
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.